NeuBase Therapeutics (NBSE)
(Delayed Data from NSDQ)
$0.42 USD
0.00 (0.10%)
Updated May 1, 2024 11:15 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NBSE 0.42 0.00(0.10%)
Will NBSE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for NBSE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBSE
NeuBase (NBSE) Surges 107% on New Shareholder Acquiring Stake
What Makes NeuBase (NBSE) a New Strong Buy Stock
NBSE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for January 20th
New Strong Buy Stocks for January 20th
NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce
Other News for NBSE
12 Health Care Stocks Moving In Friday's After-Market Session
NeuBase Therapeutics Announces Receipt of Notice from Nasdaq
NeuBase Therapeutics announces receipt of Nasdaq notice
Biotech Alert: Searches spiking for these stocks today
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session